VAX014, an Oncolytic Therapy, Reduces Adenomas and Modifies Colon Microenvironment in Mouse Model of CRC
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24129993 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Shea F Grenier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Molecular Biology Institute, San Diego State University, San Diego, CA 92182, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Adenoma, Adenomatous Polyps, Colonic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCI, California State University Program for Education and Research in Biotechnology (CSUPERB).
Abstract (Originalsprache)
Colorectal cancer (CRC) remains the third most common form of cancer and, despite its reduced mortality, results in over 50,000 deaths annually, highlighting the need for novel therapeutic approaches. VAX014 is a novel clinical-stage, oncolytic bacterial minicell-based therapy shown to elicit protective antitumor immune responses in cancer, but it has not been fully evaluated in CRC. Here, VAX014 was demonstrated to induce oncolysis in CRC cell lines in vitro and was evaluated in vivo, both as a prophylactic (before spontaneous development of adenomatous polyps) and as a neoadjuvant treatment using the Fabp-CreXApcfl468 preclinical animal model of colon cancer. As a prophylactic, VAX014 significantly reduced the size and number of adenomas without inducing long term changes in the gene expression of inflammatory, T helper 1 antitumor, and immunosuppression markers. In the presence of adenomas, a neoadjuvant VAX014 treatment reduced the number of tumors, induced the gene expression of antitumor TH1 immune markers in adenomas, and promoted the expansion of the probiotic bacterium Akkermansia muciniphila. The neoadjuvant VAX014 treatment was associated with decreased Ki67 proliferation in vivo, suggesting that VAX014 inhibits adenoma development through both oncolytic and immunotherapeutic effects. Combined, these data support the potential of VAX014 treatment in CRC and “at risk” polyp-bearing or early adenocarcinoma populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biology, Molecular Biology Institute, San Diego State University, San Diego, CA 92182, USA.
- Vaxiion Therapeutics, San Diego, CA 92121, USA.
ORCID-Profile: Shea F Grenier, Katherine A Reil, Savannah Sawaged, Shingo Tsuji
Förderung
- NCI NIH HHS
- NCI
- California State University Program for Education and Research in Biotechnology (CSUPERB)
- Vaxiion Therapeutics
Zitieren
APA
Grenier, S. F., Khan, M. W., Reil, K. A., Sawaged, S., Tsuji, S., Giacalone, M. J., Tian, M., & McGuire, K. L. (2023). VAX014, an Oncolytic Therapy, Reduces Adenomas and Modifies Colon Microenvironment in Mouse Model of CRC. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24129993
Vancouver
Grenier SF, Khan MW, Reil KA, Sawaged S, Tsuji S, Giacalone MJ, et al. VAX014, an Oncolytic Therapy, Reduces Adenomas and Modifies Colon Microenvironment in Mouse Model of CRC. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24129993
BibTeX
@article{Grenier2023,
author = {Grenier, Shea F and Khan, Mohammad W and Reil, Katherine A and Sawaged, Savannah and Tsuji, Shingo and Giacalone, Matthew J and Tian, Mengxi and McGuire, Kathleen L},
title = {VAX014, an Oncolytic Therapy, Reduces Adenomas and Modifies Colon Microenvironment in Mouse Model of CRC},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24129993}
}
EUVIMED